The following data were collected from the medical records of eligible patients: age, sex, PS just before the initiation of PD‐1/PD‐L1 inhibitor therapy, histology, stage, PD‐L1 tumor proportion score (TPS) and driver oncogenes when available, number and types of prior treatments, and the type of PD‐1/PD‐L1 inhibitor received. This evidence concerns the gene CD274 and neoplasm.